ArticleCancers2026
Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Adverse childhood events (ACEs) represent a major public health burden in the United States, as exposure to ACEs increases the risk of mental health disorders, cardiovascular disease, obesity, and cancer and can greatly affect quality of life. Although the effects of ACEs on physiology are complex, significant evidence suggests that ACEs may affect the immune system later in life. As the field of immunotherapy gains prominence in cancer treatment, it becomes imperative to explore how ACEs may impact cancer immunotherapy. Brain cancer, especially glioblastoma multiforme (GBM), has a very poor prognosis and remains a challenging disease to treat. Immunotherapy approaches are being actively investigated. To address this, we aim to raise awareness of the potential connection between ACEs, brain cancer, and cancer immunotherapy. Through a review of the current biomedical literature, we synthesized current findings into a commentary on how early-life adversity may influence the immune response within the central nervous system. It is the intention of this commentary to generate hypothesis-driven research within the nascent and emerging field of neuro-psycho-immunology in neuro-oncology. Given that the relationship between ACEs and brain cancer immunotherapy remains vastly understudied, this commentary has significant potential to generate insightful discussions among clinicians and scientists to guide further clinical and basic research towards anticipating which patients stand to receive the most benefit from immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.